Faryal Altaf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Faryal Altaf has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Zaheer Qureshi
Department of Internal Medicine, School of Medicine at Quinnipiac University, Bridgeport, CT
11 shared publications - Shivendra Mbbs Shah
Nepalgunj Medical College, Chisapani, Nepal
5 shared publications - Abdur Jamil
Department of Medicine, Samaritan Medical Centre
4 shared publications - Haider Ghazanfar
Internal Medicine, BronxCare Health System, New York, USA
4 shared publications Misbahuddin Khaja
Icahn Sch Med Mt Sinai, Bronx Care Hlth Syst, Internal Med Pulm & Crit Care, New York, NY USA
4 shared publicationsZaheer A Qureshi
Medicine, Frank H. Netter MD School of Medicine, Quinnipiac University, Bridgeport, USA
4 shared publications
Latest Publications
- Open Access
- 9 November 2025
- Published by Springer Nature in Cureus
- Vol. 17  (11)
Conjugated Hyperbilirubinemia in a Patient With COVID-19: A Case Report and Literature Review
Coronavirus disease 2019 (COVID-19) was first reported at the end of 2019 and soon evolved into a deadly pandemic of the century. It has a myriad of clinical presentations and is associated with significant mortality and morbidity. We report a case of a 49-year-old Hispanic man who presented to the emergency department with complaints of productive cough, shortness of breath, fever, and body aches for the past five days. On clinical examination, he was noted to have jaundice. Laboratory results revealed conjugated hyperbilirubinemia and elevated alkaline phosphatase. The patient tested positive for COVID-19 and appropriate treatment was initiated as per hospital protocols. All potential causes of hyperbilirubinemia were systematically excluded, including autoimmune, metabolic, hemolytic, septic, drug-induced, parasitic, and biliary etiologies. Hyperbilirubinemia improved with the treatment of COVID-19. All other causes of hyperbilirubinemia must be excluded in these individuals before attributing it to COVID-19. Further research is needed to understand the disease and to guide appropriate therapy.
- 9 November 2025
- Published by Springer Nature in Cureus
- Vol. 17  (11)
Open AccessConjugated Hyperbilirubinemia in a Patient With COVID-19: A Case Report and Literature Review
Coronavirus disease 2019 (COVID-19) was first reported at the end of 2019 and soon evolved into a deadly pandemic of the century. It has a myriad of clinical presentations and is associated with significant mortality and morbidity. We report a case of a 49-year-old Hispanic man who presented to the emergency department with complaints of productive cough, shortness of breath, fever, and body aches for the past five days. On clinical examination, he was noted to have jaundice. Laboratory results revealed conjugated hyperbilirubinemia and elevated alkaline phosphatase. The patient tested positive for COVID-19 and appropriate treatment was initiated as per hospital protocols. All potential causes of hyperbilirubinemia were systematically excluded, including autoimmune, metabolic, hemolytic, septic, drug-induced, parasitic, and biliary etiologies. Hyperbilirubinemia improved with the treatment of COVID-19. All other causes of hyperbilirubinemia must be excluded in these individuals before attributing it to COVID-19. Further research is needed to understand the disease and to guide appropriate therapy.
- Open Access
- 21 May 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87  (6) , 3244-3253
Liquid biopsies for early detection and monitoring of cancer: advances, challenges, and future directions
Objective: The article offers an extensive survey of the progressions, problems, and future trends of liquid biopsies in the early discovery and surveillance of cancer. Liquid biopsies can detect signals associated with cancer by looking at biological fluids like cerebrospinal fluid, blood, or urine, making them a less invasive alternative to traditional tissue biopsies. Methods: The review explores the molecular biology and techniques behind liquid biopsy, including circulating tumor DNA, circulatory tumor cells, and exosomes. It evaluates clinical applications of liquid biopsy across different cancer types, showing their potential for early diagnosis, monitoring disease progression, and therapy response prediction. Results: The article identifies several critical issues with liquid biopsies, including achieving a balance between high sensitivity and specificity, standardizing protocols, addressing technological heterogeneity, and ensuring cost-effectiveness and accessibility. Also, ethical issues about informed consent, data privacy, incidental findings management, and equal testing access have been examined in this context. Conclusion: Finally, this article sheds light on future developments in liquid biopsies, such as enhanced specificity, sensitivity, and integration with artificial intelligence methods.
- 21 May 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87  (6) , 3244-3253
Open AccessLiquid biopsies for early detection and monitoring of cancer: advances, challenges, and future directions
Objective: The article offers an extensive survey of the progressions, problems, and future trends of liquid biopsies in the early discovery and surveillance of cancer. Liquid biopsies can detect signals associated with cancer by looking at biological fluids like cerebrospinal fluid, blood, or urine, making them a less invasive alternative to traditional tissue biopsies. Methods: The review explores the molecular biology and techniques behind liquid biopsy, including circulating tumor DNA, circulatory tumor cells, and exosomes. It evaluates clinical applications of liquid biopsy across different cancer types, showing their potential for early diagnosis, monitoring disease progression, and therapy response prediction. Results: The article identifies several critical issues with liquid biopsies, including achieving a balance between high sensitivity and specificity, standardizing protocols, addressing technological heterogeneity, and ensuring cost-effectiveness and accessibility. Also, ethical issues about informed consent, data privacy, incidental findings management, and equal testing access have been examined in this context. Conclusion: Finally, this article sheds light on future developments in liquid biopsies, such as enhanced specificity, sensitivity, and integration with artificial intelligence methods.
- Open Access
- 12 November 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86  (12) , 7290-7298
Advancements in breast cancer management: a comprehensive review of ribociclib combined with endocrine therapy
Background: In this review, the complicated landscape of breast cancer management is explored with a focus on the promising synergies between ribociclib and endocrine therapy. Ribociclib mainly acts as a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, which disrupts cell cycle progression necessary for tumor growth. This, in combination with endocrine therapy, aims to produce hormone receptor-positive breast cancers, which is a very relevant subtype with challenging therapeutics. Methods: A comprehensive review was conducted using multiple databases, PubMed, Embase, Scopus, Cochrane Library, and Web of Science, covering the period from January 1990 to May 2024. Results: Pharmacokinetic studies underscore the efficacy and tolerability of ribociclib, thus providing vital information for dose adjustments, particularly among patients with renal and hepatic impairments. Ribociclib’s value in extending progression-free survival and improving overall survival has been shown by clinical trials such as the MONALEESA series. Quality of life considerations and patient-reported outcomes from these trials indicate that ribociclib has a broader effect on the well-being of the patients. However, despite the success experienced by this drug in clinical practice, it still has some side effects, including hematologic toxicity, hepatotoxicity, and thromboembolism associated with it. Ribociclib resistance mechanisms are multifaceted mixtures comprising genetic variations or mutations, compensatory signaling pathways, and epigenomic changes. While overcoming resistance remains challenging, ongoing research seeks to reconcile. Conclusion: Ribociclib combined with endocrine therapy represents a significant advancement in breast cancer treatment, albeit with challenges that necessitate ongoing research and holistic patient care approaches.
- 12 November 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86  (12) , 7290-7298
Open AccessAdvancements in breast cancer management: a comprehensive review of ribociclib combined with endocrine therapy
Background: In this review, the complicated landscape of breast cancer management is explored with a focus on the promising synergies between ribociclib and endocrine therapy. Ribociclib mainly acts as a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, which disrupts cell cycle progression necessary for tumor growth. This, in combination with endocrine therapy, aims to produce hormone receptor-positive breast cancers, which is a very relevant subtype with challenging therapeutics. Methods: A comprehensive review was conducted using multiple databases, PubMed, Embase, Scopus, Cochrane Library, and Web of Science, covering the period from January 1990 to May 2024. Results: Pharmacokinetic studies underscore the efficacy and tolerability of ribociclib, thus providing vital information for dose adjustments, particularly among patients with renal and hepatic impairments. Ribociclib’s value in extending progression-free survival and improving overall survival has been shown by clinical trials such as the MONALEESA series. Quality of life considerations and patient-reported outcomes from these trials indicate that ribociclib has a broader effect on the well-being of the patients. However, despite the success experienced by this drug in clinical practice, it still has some side effects, including hematologic toxicity, hepatotoxicity, and thromboembolism associated with it. Ribociclib resistance mechanisms are multifaceted mixtures comprising genetic variations or mutations, compensatory signaling pathways, and epigenomic changes. While overcoming resistance remains challenging, ongoing research seeks to reconcile. Conclusion: Ribociclib combined with endocrine therapy represents a significant advancement in breast cancer treatment, albeit with challenges that necessitate ongoing research and holistic patient care approaches.
- 8 November 2024
- Published by Springer Nature in Annals of Hematology
- Vol. 103  (12) , 4901-4912
Efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: a systematic review and meta-analysis
- 8 November 2024
- Published by Springer Nature in Annals of Hematology
- Vol. 103  (12) , 4901-4912
Efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: a systematic review and meta-analysis
- Open Access
- 30 September 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86  (11) , 6585-6597
Breaking boundaries: exploring recent advances in anticoagulation and thrombosis management: a comprehensive review
Background: Thromboembolic disorders globally contribute to morbidity and mortality, emphasizing adequate anticoagulation and thrombosis management. Therapeutic advances are essential in preventing complications like pulmonary embolism, stroke, and myocardial infarction. This review summarizes recent anticoagulation advances, current challenges, future directions, and novel anticoagulants and drug delivery systems on clinical outcomes. Methods: This paper assesses the effectiveness and safety of new anticoagulants through a systematic review of recent clinical trials, meta-analyses, and guideline publications. Key studies, including PACIFIC-AF, RIVER, ENAVLE, ENVISAGE-TAVI AF, and ARCADIA, were analyzed to provide a perspective on therapeutic advancements. Results: The review highlights key findings from vital clinical trials. Asundexian, in the PACIFIC-AF trial, demonstrated a 34% reduction in bleeding events compared to Apixaban. In the RIVER trial, Rivaroxaban reduced significant bleeding events by 20% compared to warfarin in patients with bioprosthetic mitral valves. In the ENAVLE trial, Edoxaban achieved a 3.7% decrease in thromboembolic events compared to warfarin without increasing significant bleeding rates. In the ENVISAGE-TAVI AF trial, edoxaban was noninferior to VKAs in preventing thromboembolic events but showed a slight increase in major bleeding events by 1.5%. Lastly, the ARCADIA trial highlighted that apixaban did not significantly reduce recurrent stroke risk compared to aspirin, with both treatments having an annualized stroke rate of 4.4%. Conclusion: Advances in anticoagulant therapies and drug delivery systems aim to enhance patients’ clinical outcomes for thromboembolic disorders. While recent trials show promising data, ongoing patient-specific responses and monitoring challenges require further research. Continuous innovation and investigation are essential to refine anticoagulation practices and tailor treatments.
- 30 September 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86  (11) , 6585-6597
Open AccessBreaking boundaries: exploring recent advances in anticoagulation and thrombosis management: a comprehensive review
Background: Thromboembolic disorders globally contribute to morbidity and mortality, emphasizing adequate anticoagulation and thrombosis management. Therapeutic advances are essential in preventing complications like pulmonary embolism, stroke, and myocardial infarction. This review summarizes recent anticoagulation advances, current challenges, future directions, and novel anticoagulants and drug delivery systems on clinical outcomes. Methods: This paper assesses the effectiveness and safety of new anticoagulants through a systematic review of recent clinical trials, meta-analyses, and guideline publications. Key studies, including PACIFIC-AF, RIVER, ENAVLE, ENVISAGE-TAVI AF, and ARCADIA, were analyzed to provide a perspective on therapeutic advancements. Results: The review highlights key findings from vital clinical trials. Asundexian, in the PACIFIC-AF trial, demonstrated a 34% reduction in bleeding events compared to Apixaban. In the RIVER trial, Rivaroxaban reduced significant bleeding events by 20% compared to warfarin in patients with bioprosthetic mitral valves. In the ENAVLE trial, Edoxaban achieved a 3.7% decrease in thromboembolic events compared to warfarin without increasing significant bleeding rates. In the ENVISAGE-TAVI AF trial, edoxaban was noninferior to VKAs in preventing thromboembolic events but showed a slight increase in major bleeding events by 1.5%. Lastly, the ARCADIA trial highlighted that apixaban did not significantly reduce recurrent stroke risk compared to aspirin, with both treatments having an annualized stroke rate of 4.4%. Conclusion: Advances in anticoagulant therapies and drug delivery systems aim to enhance patients’ clinical outcomes for thromboembolic disorders. While recent trials show promising data, ongoing patient-specific responses and monitoring challenges require further research. Continuous innovation and investigation are essential to refine anticoagulation practices and tailor treatments.
- Open Access
- 21 June 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86  (8) , 4647-4656
Pembrolizumab in combination with trastuzumab for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer
Introduction: Gastric cancer remains a challenging malignancy with a high global mortality rate. Recent advances in targeted therapy and immunotherapy have shown promise in improving patient outcomes. This paper reviews the impact of incorporating targeted agents such as trastuzumab and immunotherapeutic agents like pembrolizumab into standard chemotherapy regimens for gastric cancer treatment. Methods: A comprehensive analysis was conducted on pivotal clinical trials, including KEYNOTE-590, KEYNOTE-811, and ToGA, focusing on their methodologies, patient populations, treatment regimens, and outcome measures. The review also explored emerging research avenues in precision medicine, particularly genomic sequencing and biomarker identification. Aim: To assess the efficacy and survival benefits of adding trastuzumab and pembrolizumab to standard chemotherapy in the treatment of gastric cancer and to outline future directions in gastric cancer research. Results: Including trastuzumab and pembrolizumab in treatment regimens for human epidermal growth factor receptor 2 (HER2)-positive and PD-L1-expressing gastric cancers significantly improved progression-free and overall survival rates compared to chemotherapy alone. These findings highlight the potential of personalized therapy in enhancing treatment outcomes. Furthermore, ongoing research into the gastric cancer microenvironment and the role of the microbiome suggests novel targets for future therapeutic interventions. Conclusion: The integration of targeted and immunotherapeutic agents with traditional chemotherapy represents a pivotal shift in gastric cancer treatment, moving towards more personalized and effective regimens.
- 21 June 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86  (8) , 4647-4656
Open AccessPembrolizumab in combination with trastuzumab for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer
Introduction: Gastric cancer remains a challenging malignancy with a high global mortality rate. Recent advances in targeted therapy and immunotherapy have shown promise in improving patient outcomes. This paper reviews the impact of incorporating targeted agents such as trastuzumab and immunotherapeutic agents like pembrolizumab into standard chemotherapy regimens for gastric cancer treatment. Methods: A comprehensive analysis was conducted on pivotal clinical trials, including KEYNOTE-590, KEYNOTE-811, and ToGA, focusing on their methodologies, patient populations, treatment regimens, and outcome measures. The review also explored emerging research avenues in precision medicine, particularly genomic sequencing and biomarker identification. Aim: To assess the efficacy and survival benefits of adding trastuzumab and pembrolizumab to standard chemotherapy in the treatment of gastric cancer and to outline future directions in gastric cancer research. Results: Including trastuzumab and pembrolizumab in treatment regimens for human epidermal growth factor receptor 2 (HER2)-positive and PD-L1-expressing gastric cancers significantly improved progression-free and overall survival rates compared to chemotherapy alone. These findings highlight the potential of personalized therapy in enhancing treatment outcomes. Furthermore, ongoing research into the gastric cancer microenvironment and the role of the microbiome suggests novel targets for future therapeutic interventions. Conclusion: The integration of targeted and immunotherapeutic agents with traditional chemotherapy represents a pivotal shift in gastric cancer treatment, moving towards more personalized and effective regimens.
- Open Access
- 19 June 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86  (8) , 4624-4633
Elacestrant in the treatment landscape of ER-positive, HER2-negative, ESR1-mutated advanced breast cancer: a contemporary narrative review
Introduction: Estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2−) breast cancer with ESR1 mutations presents a significant therapeutic challenge due to its adaptive resistance mechanisms to chemotherapy, especially endocrine treatment. Elacestrant, a novel oral selective estrogen receptor degrader (SERD), has emerged as a promising agent in this treatment-resistant era. Method: A comprehensive search was conducted on pivotal clinical trials, including the RAD1901-005 Trial, EMERALD TRIAL, ELIPSE, and ELEVATE, focusing on their methodologies, patient populations, treatment regimens, and outcomes. Discussion: This narrative review describes the available preclinical and clinical evidence on elacestrant, focusing on its pharmacodynamics, pharmacokinetics, efficacy, and safety within the existing literature. Elacestrant has demonstrated excellent activity against ESR1 mutations associated with resistance to first-line endocrine therapies. Clinical trials have shown improved progression-free survival in patients with advanced ER+/HER2−, ESR1-mutated breast cancer. Safety profiles indicate a tolerable side effect spectrum consistent with other agents. Its oral bioavailability offers a convenient alternative to injectable SERDs, with potential implications for patient adherence and quality of life. The review also discusses the comparative efficacy of elacestrant relative to existing endocrine therapies and its possible use in combination regimens. Conclusion: Ongoing clinical trials assessing elacestrant and other SERDs will yield data that might aid clinicians in determining the optimal selection and order of endocrine treatment drugs for ER+ breast cancer. The integration of targeted and immunotherapeutic agents with traditional chemotherapy represents a pivotal shift in Breast Cancer treatment, moving towards more personalized and effective regimens.
- 19 June 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86  (8) , 4624-4633
Open AccessElacestrant in the treatment landscape of ER-positive, HER2-negative, ESR1-mutated advanced breast cancer: a contemporary narrative review
Introduction: Estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2−) breast cancer with ESR1 mutations presents a significant therapeutic challenge due to its adaptive resistance mechanisms to chemotherapy, especially endocrine treatment. Elacestrant, a novel oral selective estrogen receptor degrader (SERD), has emerged as a promising agent in this treatment-resistant era. Method: A comprehensive search was conducted on pivotal clinical trials, including the RAD1901-005 Trial, EMERALD TRIAL, ELIPSE, and ELEVATE, focusing on their methodologies, patient populations, treatment regimens, and outcomes. Discussion: This narrative review describes the available preclinical and clinical evidence on elacestrant, focusing on its pharmacodynamics, pharmacokinetics, efficacy, and safety within the existing literature. Elacestrant has demonstrated excellent activity against ESR1 mutations associated with resistance to first-line endocrine therapies. Clinical trials have shown improved progression-free survival in patients with advanced ER+/HER2−, ESR1-mutated breast cancer. Safety profiles indicate a tolerable side effect spectrum consistent with other agents. Its oral bioavailability offers a convenient alternative to injectable SERDs, with potential implications for patient adherence and quality of life. The review also discusses the comparative efficacy of elacestrant relative to existing endocrine therapies and its possible use in combination regimens. Conclusion: Ongoing clinical trials assessing elacestrant and other SERDs will yield data that might aid clinicians in determining the optimal selection and order of endocrine treatment drugs for ER+ breast cancer. The integration of targeted and immunotherapeutic agents with traditional chemotherapy represents a pivotal shift in Breast Cancer treatment, moving towards more personalized and effective regimens.
- Open Access
- 22 April 2024
- Published by Springer Nature in Cureus
- Vol. 16  (4) , e58775
Crushing Muscles: A Case Study on Rhabdomyolysis, Renal Failure, and Compartment Syndrome Triggered by Pre-Workout Supplement Abuse
The use of steroids and protein-based dietary supplements for muscle enhancement is prevalent in contemporary society. While these products promise increased muscle mass and strength, they carry significant risks, including severe medical complications. The consumption of these supplements has been linked to adverse symptoms, including dehydration, gastrointestinal distress, dizziness, and alterations in heart rate and blood pressure, primarily due to ingredients like creatine, arginine, and caffeine. Following the proper dosage, ensuring adequate hydration, and consulting a healthcare provider to verify if the supplement's components could affect any pre-existing conditions is recommended. Indiscriminate use of these products, including taurine, can lead to serious side effects. We present a 36-year-old patient with severe rhabdomyolysis, life-threatening acid-base imbalance, renal and liver injury, and peripheral neuropathy associated with the use of performance-enhanced unregulated supplements and exercise. This case highlights the importance of recognizing and managing complications related to exercise-aid supplements, emphasizing early identification and management. Increasing social awareness and research on those products is highly needed to avoid supplement-associated complications and potential long-term disabilities.
- 22 April 2024
- Published by Springer Nature in Cureus
- Vol. 16  (4) , e58775
Open AccessCrushing Muscles: A Case Study on Rhabdomyolysis, Renal Failure, and Compartment Syndrome Triggered by Pre-Workout Supplement Abuse
The use of steroids and protein-based dietary supplements for muscle enhancement is prevalent in contemporary society. While these products promise increased muscle mass and strength, they carry significant risks, including severe medical complications. The consumption of these supplements has been linked to adverse symptoms, including dehydration, gastrointestinal distress, dizziness, and alterations in heart rate and blood pressure, primarily due to ingredients like creatine, arginine, and caffeine. Following the proper dosage, ensuring adequate hydration, and consulting a healthcare provider to verify if the supplement's components could affect any pre-existing conditions is recommended. Indiscriminate use of these products, including taurine, can lead to serious side effects. We present a 36-year-old patient with severe rhabdomyolysis, life-threatening acid-base imbalance, renal and liver injury, and peripheral neuropathy associated with the use of performance-enhanced unregulated supplements and exercise. This case highlights the importance of recognizing and managing complications related to exercise-aid supplements, emphasizing early identification and management. Increasing social awareness and research on those products is highly needed to avoid supplement-associated complications and potential long-term disabilities.
- Open Access
- 11 April 2024
- Published by Springer Nature in Cureus
- Vol. 16  (4) , e57985
Segmental Shielding: A Rare Case of Acute Respiratory Distress Syndrome with Middle Lobe Sparing
Acute respiratory distress syndrome (ARDS) presents a formidable challenge in critical care, often resulting in high mortality rates, particularly in severe cases or those compounded by preexisting conditions. Despite substantial advancements in critical care, the heterogeneous nature of ARDS necessitates nuanced clinical approaches. ARDS is generally diagnosed through clinical evaluation, radiographic imaging, and laboratory tests, as well as acute onset, bilateral lung infiltrates on imaging, and a partial pressure of oxygen in arterial blood (PaO2)/fraction of inspiratory oxygen concentration (FiO2) ratio of less than 300 mmHg. Management involves measurements to improve oxygenation and provide mechanical ventilation to assist breathing. The typical manifestation of ARDS is diffuse lung involvement, which affects multiple lobes symmetrically. Here, we report an unusual case of ARDS in a 53-year-old female who was brought into the hospital in an unresponsive state, exhibiting hypoxic and hypotension requiring intubation. Subsequent imaging revealed a distinctive pattern: the preservation of the right middle lobe, diverging from the conventional diffuse pulmonary affliction. This case underscores the need for clinical vigilance and adaptability, as such atypical presentations can confound diagnosis and management, posing unique clinical challenges. This case highlights the importance of recognizing ARDS' diverse presentations. Moreover, understanding the mechanisms behind the lobar sparing could provide greater insight into the disease heterogeneity and guide tailored therapeutic approaches. The imperative for further research into these uncommon presentations is clear, as it may be vital to improving outcomes for a broader spectrum of ARDS patients.
- 11 April 2024
- Published by Springer Nature in Cureus
- Vol. 16  (4) , e57985
Open AccessSegmental Shielding: A Rare Case of Acute Respiratory Distress Syndrome with Middle Lobe Sparing
Acute respiratory distress syndrome (ARDS) presents a formidable challenge in critical care, often resulting in high mortality rates, particularly in severe cases or those compounded by preexisting conditions. Despite substantial advancements in critical care, the heterogeneous nature of ARDS necessitates nuanced clinical approaches. ARDS is generally diagnosed through clinical evaluation, radiographic imaging, and laboratory tests, as well as acute onset, bilateral lung infiltrates on imaging, and a partial pressure of oxygen in arterial blood (PaO2)/fraction of inspiratory oxygen concentration (FiO2) ratio of less than 300 mmHg. Management involves measurements to improve oxygenation and provide mechanical ventilation to assist breathing. The typical manifestation of ARDS is diffuse lung involvement, which affects multiple lobes symmetrically. Here, we report an unusual case of ARDS in a 53-year-old female who was brought into the hospital in an unresponsive state, exhibiting hypoxic and hypotension requiring intubation. Subsequent imaging revealed a distinctive pattern: the preservation of the right middle lobe, diverging from the conventional diffuse pulmonary affliction. This case underscores the need for clinical vigilance and adaptability, as such atypical presentations can confound diagnosis and management, posing unique clinical challenges. This case highlights the importance of recognizing ARDS' diverse presentations. Moreover, understanding the mechanisms behind the lobar sparing could provide greater insight into the disease heterogeneity and guide tailored therapeutic approaches. The imperative for further research into these uncommon presentations is clear, as it may be vital to improving outcomes for a broader spectrum of ARDS patients.
- Open Access
- 10 April 2024
- Published by Springer Nature in Cureus
- Vol. 16  (4) , e57994
Uncommon Manifestation: Thrombotic Thrombocytopenic Purpura Presenting Solely as Petechial Rash
Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening disorder typically presenting with a classic pentad of symptoms: thrombocytopenia, microangiopathic hemolytic anemia, neurological abnormalities, renal dysfunction, and fever. This report explores an unusual presentation of TTP in a 47year-old female with a medical history of hypertension, hyperlipidemia, and chronic TTP, who exhibited only petechial rashes, generalized weakness, and headache. Notably, the petechial rash, a less common manifestation of TTP, became a pivotal clue for the diagnosis, underscoring the necessity for vigilance even when classic symptoms are absent. This case reinforces the imperative of a high suspicion index for TTP, especially in patients with thrombocytopenia and hemolytic anemia, irrespective of other traditional signs. Plasmapheresis remains the treatment cornerstone, removing autoantibodies and replenishing ADAMTS13, as evidenced by the patient's initial response. The administration of rituximab, targeting B cells to mitigate autoantibody production against ADAMTS13, featured prominently in her management, aligning with its recognized role in refractory or relapsing TTP cases. Despite an encouraging response to rituximab, a subsequent decline in platelet count indicated the unpredictable nature of TTP and the necessity for multipronged therapeutic strategies. The patient's medical background and persistently low ADAMTS13 levels hinted at a chronic relapsing trajectory associated with increased morbidity and mortality. This necessitates ongoing vigilance and treatment flexibility. Highlighting this atypical TTP presentation, the report calls for immediate, robust intervention, serving as a critical reminder of the heterogeneity of TTP manifestations and the complexities in its management, thereby contributing to broader clinical awareness and improved patient prognoses.
- 10 April 2024
- Published by Springer Nature in Cureus
- Vol. 16  (4) , e57994
Open AccessUncommon Manifestation: Thrombotic Thrombocytopenic Purpura Presenting Solely as Petechial Rash
Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening disorder typically presenting with a classic pentad of symptoms: thrombocytopenia, microangiopathic hemolytic anemia, neurological abnormalities, renal dysfunction, and fever. This report explores an unusual presentation of TTP in a 47year-old female with a medical history of hypertension, hyperlipidemia, and chronic TTP, who exhibited only petechial rashes, generalized weakness, and headache. Notably, the petechial rash, a less common manifestation of TTP, became a pivotal clue for the diagnosis, underscoring the necessity for vigilance even when classic symptoms are absent. This case reinforces the imperative of a high suspicion index for TTP, especially in patients with thrombocytopenia and hemolytic anemia, irrespective of other traditional signs. Plasmapheresis remains the treatment cornerstone, removing autoantibodies and replenishing ADAMTS13, as evidenced by the patient's initial response. The administration of rituximab, targeting B cells to mitigate autoantibody production against ADAMTS13, featured prominently in her management, aligning with its recognized role in refractory or relapsing TTP cases. Despite an encouraging response to rituximab, a subsequent decline in platelet count indicated the unpredictable nature of TTP and the necessity for multipronged therapeutic strategies. The patient's medical background and persistently low ADAMTS13 levels hinted at a chronic relapsing trajectory associated with increased morbidity and mortality. This necessitates ongoing vigilance and treatment flexibility. Highlighting this atypical TTP presentation, the report calls for immediate, robust intervention, serving as a critical reminder of the heterogeneity of TTP manifestations and the complexities in its management, thereby contributing to broader clinical awareness and improved patient prognoses.